Paclitaxel drug coated balloons (DCBs) should provide optimal drug transfer exclusively to the target tissue. The aim of this study was to evaluate the particle loss by handling during angioplasty. A robotic arm was developed for systematic and reproducible drug abrasion experiments. The contact force on eight different commercially available DCB types was gradually increased, and high-resolution microscopic images of the deflated and inflated balloons were recorded. Three types of DCBs were classified: no abrasion of the drug in both statuses (deflated and inflated), significant abrasion only in the inflated status, and significant abrasion in both statuses. Quantitative measurements via image processing confirmed the qualitative classific...
Peripheral artery disease is a cardiovascular disease characterized by a narrowing of arteries that ...
Background/objectives: Preclinical investigations have suggested that coating technology is crucial ...
Aim: To evaluate the technical and clinical success, primary patency (PP) and complications of angio...
Background Drug coated balloons (DCB) with paclitaxel (Ptx) dose of 2–3.5 μg/mm2 balloon surface inh...
Background/Objectives: Drug-coated balloon therapy for diseased superficial femoral arteries remain...
Abstract Drug‐coated balloon (DCB) percutaneous interventional therapy allows for durable reopening ...
Item does not contain fulltextThe use of drug-eluting balloons for treatment of long-segment femorop...
Monika Herten,1 Giovanni B Torsello,1,2 Eva Schönefeld,3 Stefan Stahlhoff2 1Department of Vascu...
ObjectivesThis study sought to evaluate the safety and efficacy of the Lutonix drug-coated balloon (...
OBJECTIVES: This study sought to evaluate vascular drug uptake, distribution and response of second-...
The role of paclitaxel-coated balloons has been established in the coronary and peripheral arterial ...
The most common treatment for obstructive coronary artery disease (CAD) is the implantation of a per...
Peripheral artery disease (PAD), the narrowing of peripheral arteries located in areas such as the a...
Objectives. The present study was designed to compare the characteristics and performance regarding ...
Background—Drug-coated balloons are increasingly used for peripheral vascular disease, and, yet, mec...
Peripheral artery disease is a cardiovascular disease characterized by a narrowing of arteries that ...
Background/objectives: Preclinical investigations have suggested that coating technology is crucial ...
Aim: To evaluate the technical and clinical success, primary patency (PP) and complications of angio...
Background Drug coated balloons (DCB) with paclitaxel (Ptx) dose of 2–3.5 μg/mm2 balloon surface inh...
Background/Objectives: Drug-coated balloon therapy for diseased superficial femoral arteries remain...
Abstract Drug‐coated balloon (DCB) percutaneous interventional therapy allows for durable reopening ...
Item does not contain fulltextThe use of drug-eluting balloons for treatment of long-segment femorop...
Monika Herten,1 Giovanni B Torsello,1,2 Eva Schönefeld,3 Stefan Stahlhoff2 1Department of Vascu...
ObjectivesThis study sought to evaluate the safety and efficacy of the Lutonix drug-coated balloon (...
OBJECTIVES: This study sought to evaluate vascular drug uptake, distribution and response of second-...
The role of paclitaxel-coated balloons has been established in the coronary and peripheral arterial ...
The most common treatment for obstructive coronary artery disease (CAD) is the implantation of a per...
Peripheral artery disease (PAD), the narrowing of peripheral arteries located in areas such as the a...
Objectives. The present study was designed to compare the characteristics and performance regarding ...
Background—Drug-coated balloons are increasingly used for peripheral vascular disease, and, yet, mec...
Peripheral artery disease is a cardiovascular disease characterized by a narrowing of arteries that ...
Background/objectives: Preclinical investigations have suggested that coating technology is crucial ...
Aim: To evaluate the technical and clinical success, primary patency (PP) and complications of angio...